Welcome!

News Feed Item

Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation

Protein Degradation Platform Represents a New Class of Drugs

NEW HAVEN, Conn., Sept. 26, 2013 /PRNewswire/ -- Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced it has raised $15 million in Series A funds and $4.25 million in financial support, $1 million of which is in the form of equity, from the Connecticut Department of Economic and Community Development and Connecticut Innovations. Investors in the Series A round include co-leads Canaan Partners and 5AM Ventures along with Connecticut Innovations and Elm Street Ventures. The funds will support the development of the company's technology which has primary application in multiple oncology indications and potential in inflammatory, autoimmune and rare diseases.

Arvinas is built on the research of Craig Crews, PhD, Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and professor of Chemistry and Pharmacology at Yale University. The new drugs being developed by Arvinas would induce a cell's own protein-degradation capabilities to bind to a particular protein and "label" it for degradation, thus removing a protein from the system entirely. This contrasts to a more traditional drug development approach that inhibits proteins.  However, only 25 percent of the body's 20,000 proteins can be inhibited. Proteins that cannot be inhibited can potentially be degraded using Arvinas' approach, radically expanding the number of disease-causing proteins that can become the targets of new drugs.

"Degrading proteins as opposed to inhibiting them has potential to open up areas of drug development that were previously closed because of the technical limitations of protein inhibition," said Tim Shannon, MD, CEO of Arvinas and Venture Partner at Canaan Partners. "The Arvinas technology platform represents an entirely new class of drugs bringing an innovative approach to treating disease."

"In addition to the fact that a very large portion of proteins cannot be blocked, inhibition is not permanent, so a disease-causing protein can eventually become active again after treatment with a drug," said Dr. Crews. "To effectively stop cancer, a drug-binding site must be inhibited 95 percent of the time, which is currently difficult to achieve. If a protein is removed entirely, that should overcome this problem."

Arvinas also announced the formation of a Scientific Advisory Board (SAB), which will help guide the development of its novel approach. Members of the SAB include Daniel D. Von Hoff, MD, Chief, distinguished professor and director of clinical translational research division at the Translational Genomics Research Institute and Chief Scientific Officer for US Oncology; Mark Murcko, PhD, former Chief Technology Officer at Vertex Pharmaceuticals; Thomas J. Lynch, Jr., MD, Director of the Yale Cancer Center and Physician-in-chief at Smilow Cancer Hospital at Yale-New Haven;  Richard Ulevitch, Venture Partner 5AM  and Professor and  Chairman Emeritus of the Department of Immunology at The Scripps Research Institute, La Jolla, California; and Peter Farina, PhD, executive in residence at Canaan Partners and former Senior Vice-President of Development at Boehringer Ingelheim.

Arvinas worked with the Yale Office of Cooperative Research (OCR) to secure intellectual property protection for the technology.

"The Arvinas team has lined up an impressive slate of supporters of the unique technology that comes out of Yale University," noted John Soderstrom, PhD, Managing Director of the Office of Cooperative Research at Yale and a member of Arvinas' Board of Directors. "Degrading proteins that are driving disease has the potential to bring about drastic changes in drug development, and we anticipate significant interest from pharmaceutical companies."

Joining Dr. Shannon and Dr. Soderstrom on the Arvinas Board of Directors will be Kush Parmar, MD PhD and a Principal at 5AM Ventures and Brad Margus, the CEO of Genome Bridge and former CEO of Envoy Therapeutics.

About the Yale Office of Cooperative Research

The Yale Office of Cooperative Research works with faculty to realize the commercial potential of their discoveries through licensing of intellectual property, identification of opportunities to partner with corporate sponsors of research and facilitating the formation of new ventures based on Yale's intellectual property. Learn more at http://www.yale.edu/ocr.

About Arvinas

Arvinas Inc. is creating a new class of drugs based on protein degradation, which has the potential to open up areas of drug development that were previously closed because of the technical limitations of target inhibition. The company's technology is built on the research of Craig Crews, PhD of Yale University and has primary application in oncology indications as well as potential in inflammatory, autoimmune and rare diseases. http://www.arvinas.com/

SOURCE Arvinas Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"When you think about the data center today, there's constant evolution, The evolution of the data center and the needs of the consumer of technology change, and they change constantly," stated Matt Kalmenson, VP of Sales, Service and Cloud Providers at Veeam Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Zerto exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clouds. The company’s flagship product, Zerto Virtual...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
WebRTC defines no default signaling protocol, causing fragmentation between WebRTC silos. SIP and XMPP provide possibilities, but come with considerable complexity and are not designed for use in a web environment. In his session at @ThingsExpo, Matthew Hodgson, technical co-founder of the Matrix.org, discussed how Matrix is a new non-profit Open Source Project that defines both a new HTTP-based standard for VoIP & IM signaling and provides reference implementations.
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
910Telecom exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and exchanges.
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
The IoT industry is now at a crossroads, between the fast-paced innovation of technologies and the pending mass adoption by global enterprises. The complexity of combining rapidly evolving technologies and the need to establish practices for market acceleration pose a strong challenge to global enterprises as well as IoT vendors. In his session at @ThingsExpo, Clark Smith, senior product manager for Numerex, discussed how Numerex, as an experienced, established IoT provider, has embraced a new m...
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, will highlight the current challenges of these transformative technologies and share strategies for preparing your organization for these changes. This “view from the top” will outline the latest trends and developm...
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...